Eloralintide (LY3841136)

The dominant downside for eloralintide is not toxicity, it is unfinishedness compounded by inaccessibility. No intrinsic life-threatening effect has been demonstrated: the phase 2 trial recorded no deaths, no pancreatitis case and serious events that appeared as isolated singletons rather than any pattern, and the twenty-year label of the only approved amylin drug carries no tumour or pancreas warning. What replaces that risk is a different one. Total human exposure to this molecule is roughly 410 people for no more than 48 weeks, an unexplained slow-heart-rate signal appeared on drug and not on placebo, and there is no lawful way to obtain it, which pushes anyone determined to try it toward unregulated powder at real expense. The side effects that do occur are frequent rather than dangerous, and the dimensions below separate those two things deliberately, because a drug people tolerate badly and a drug that harms people are different problems with different answers.

Safety Risk (2.8/5.0): No intrinsic catastrophic effect has been demonstrated for eloralintide, and the class precedent argues against inheriting one. The phase 2 trial recorded zero deaths, no pancreatitis, and lipase elevation at roughly the placebo rate, with serious events appearing as unrelated singletons across arms (registry results for NCT06230523). Pramlintide's FDA label, covering twenty years of approved amylin use, carries one boxed warning for low blood sugar with insulin, no pancreatitis warning, and two-year rodent studies showing no drug-caused tumours. What keeps this dimension from scoring lower is genuine unknown: a slow-heart-rate term appeared in 11% of the 6 mg arm and 0% of placebo with no explanation offered, no nonclinical toxicology package for this molecule is public, and 410 people cannot exclude a one-in-a-thousand event.

Side Effect Profile (2.7/5.0): Common, dose-related and unpleasant, but rarely enough to make people quit. On 9 mg the rates were nausea 33%, fatigue 43%, constipation 24% and vomiting 11%, and the 6 mg arm reported nausea at 64% and vomiting at 25%, which is worse than the higher dose and probably reflects a 28-person arm rather than a real inversion (registry results for NCT06230523). Alopecia appeared in 11% of the 9 mg arm against none on placebo, which tends to follow rapid large weight loss generally. The redeeming number remains the discontinuation rate of 2.9% against 3.8% on placebo. Frequent side effects that people tolerate score better here than rare ones that end treatment.

Financial Cost (3.3/5.0): There is no legitimate channel to price. Eloralintide is not approved, not prescribable and not compoundable, so the cost question resolves to research-chemical vendors selling laboratory powder at roughly $12 per mg, which puts a 9 mg weekly dose above $450 per month before syringes, bacteriostatic water or any testing. That is more than compounded tirzepatide costs through a telehealth service, for a product with no manufacturing oversight and no guarantee that the vial contains what the label claims. The one genuinely free route is enrolment in a phase 3 trial such as ENLIGHTEN-1, which recruits 1,980 people and covers the drug entirely.

Time/Effort Burden (2.3/5.0): One subcutaneous injection per week is a light schedule by any standard, and lighter than the daily dosing pramlintide required. The burden sits in everything around it. With no approved pen, anyone using eloralintide outside a trial is reconstituting lyophilised powder, calculating concentration, drawing into an insulin syringe and getting the arithmetic right every week, which is a real skill requirement and a real error surface. Add a titration schedule that runs 20 weeks on the best-performing step-up arm, plus weight and side-effect tracking to know whether it is working. Inside a trial, none of this applies and the burden drops sharply.

Opportunity Cost (2.8/5.0): Choosing eloralintide today means choosing 263 people of evidence over the thousands behind tirzepatide, for a comparable result. Tirzepatide reached 20.9% at 72 weeks in a trial of 2,539 people with years of subsequent real-world use (Jastreboff et al. 2022), and it is legally available. Waiting costs a person very little, because the phase 3 readout lands in 2028 and the drug will still be there. The deeper opportunity cost is the familiar one for this whole category: a weekly injection that suppresses appetite can substitute for the protein intake, resistance training and sleep that determine whether the weight lost is fat or muscle, and that substitution is invisible until the scale stops moving.

Dependency/Withdrawal (3.5/5.0): This is functional dependency rather than addiction, and it should be assumed rather than hoped against. Eloralintide produces no craving, no tolerance and no withdrawal syndrome, and there is nothing in amylin pharmacology suggesting otherwise. What it does is supply a satiety signal continuously, and when that supply stops the signal stops with it. Every drug in the broader weight-management category behaves this way, and no off-drug data exists for eloralintide to suggest an exception. Anyone starting it should plan on it being indefinite, or plan the exit before starting.

Reversibility (1.7/5.0): Stopping is clean. Eloralintide is a peptide that clears the body without leaving a structural change behind, with no taper required, no receptor damage described and no permanent effect reported in any trial. Weight regain after stopping is a durability problem, not a reversibility harm, and it is scored above rather than counted twice here. The one caveat worth stating is that no one has published a post-discontinuation follow-up for this molecule, so cleanness of washout is inferred from peptide pharmacology and the class record rather than measured directly.

Withdrawal for an adverse event occurred in 6 of 210 participants taking eloralintide, 2.9%, against 2 of 53 on placebo, 3.8%. Posted results, ClinicalTrials.gov NCT06230523